Poma­lido­mide plus low-dose dexa­metha­sone dem­onstrated sig­nif­i­cantly longer median pro­gres­sion-free survival and over­all survival at a median follow-up of 10 months

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that updated results from MM-003, a phase III multi-center, ran­dom­ized open-label study (n=455) of poma­lido­mide (marketed as POMALYST^® in the U.S. and IMNOVID^® in the E.U.) plus low-dose dexa­metha­sone, were published online ahead of print in The Lancet Oncology.

The study compared oral poma­lido­mide plus low-dose dexa­metha­sone with high-dose dexa­metha­sone in patients with refractory or re­lapsed and refractory multiple myeloma who have failed at least two prior thera­pies with both bor­tez­o­mib and lena­lido­mide, ad­min­is­tered alone or in …

Raritan, NJ (Press Release) - Janssen Research & Development, LLC (“Janssen”) announced the si­mul­ta­ne­ous sub­missions of a Biologic License Application (BLA) to the United States Food and Drug Ad­min­is­tra­tion (U.S. FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for siltuximab for the treat­ment of patients with multicentric Castleman disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative.

MCD is a rare disorder in which lym­pho­cytes, a certain type of white blood cells, are over-produced and lead to enlargement of lymph nodes.[1,2] This can cause a variety …

-The Leukemia & Lymphoma Society launches national education campaign during Blood Cancer Awareness Month in September -

White Plains, NY (Press Release) - Less than one half (46%) of adults polled in a new survey believe that blood cancers are one of three leading causes of cancer death in the U.S. In fact, blood cancers are the third leading cause of cancer death, behind cancers of the res­pira­tory system, in­­clud­ing lung cancer, and cancers of the digestive system, in­­clud­ing colorectal cancer.¹ The survey of 1,000 U.S. adults was commissioned by The Leukemia & …

Attractive Addition to Amgen's Leading Oncology Portfolio and Pipeline

Kyprolis(R) (car­filz­o­mib) for Injection Is at Early Stages of Launch in Multiple Myeloma; Showing Strong Physician Support

Acquisition Expected to Contribute to Growth and Value for Amgen Shareholders

Amgen to Host Analyst/Investor Call Monday at 8:30 a.m. EDT (5:30 a.m. PDT)

Thousand Oaks, CA and South San Francisco, CA (Press Release) - Amgen (NASDAQ: AMGN) and Onyx Pharma­ceu­ticals, Inc. (NASDAQ: ONXX) today announced that their Boards of Directors have unanimously approved a trans­­action under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of esti­mated Onyx cash.

Onyx Pharma­ceu­ticals, Inc. is a global bio­pharma­ceu­tical com­pany engaged in the devel­op­ment and com­mer­cialization of inno­va­tive ther­a­pies for im­prov­ing the lives of people with cancer. Onyx has an im­por­tant …

Stockholm (Press Release) - Oncopeptides AB, a com­pany work­ing to en­hance on­col­ogy ther­a­pies, to­day an­nounced that the first patient has been dosed as part of a Phase II study in mul­ti­ple myeloma patients with its drug can­di­date melflufen (previously called J1).

The trial is an open-label Phase II study de­signed to de­ter­mine the level of ef­fi­cacy of melflufen in com­bi­na­tion with dexa­meth­a­sone, for late stage, relapsing or relapsing/refractory patients. The pri­mary end point is, best re­sponse in accordance with the Inter­na­tional Myeloma Work­ing Group criteria during up to eight cycles of treat­ment.

The trial is being …

Edinburgh (Press Release) - Myeloma UK has opened MUK four to patient recruitment. It is the fifth trial in the last two years to open in the Myeloma UK Clinical Trial Network (CTN) which provides access to prom­is­ing myeloma drugs and aims to accelerate the process for approving new drugs and making them avail­able on the NHS.

MUK four is a Phase II trial to assess the efficacy, safety and tolerability of vorinostat in com­bi­na­tion with Velcade® (bor­tez­o­mib) and dexa­meth­a­sone (VVD) in patients with re­lapsed or re­lapsed refractory myeloma. MUK four will recruit up to 68 patients. It …

London (Press Release) - A gene that helps control the ageing process by acting as a cell’s internal clock has been linked to cancer by a major new study.

Scientists at The Institute of Cancer Research, London, found a genetic variant that influences the ageing process among four new variants they linked to myeloma – one of the most common types of blood cancer.

The study more than doubles the number of genetic variants linked to myeloma, bringing the total number to seven, and sheds important new light on the genetic causes …